Merck, announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the production of the new innovative technologies for development and discovery of drug. MDSS will be supporting early-stage biomedical startup companies with direct investment, and access to powerful Azure Cloud computing and several other opportunities to pilot the technologies in partnership with clinical and discovery scientists working at Merck.
The company will welcome applications for 12 spots for the first MDSS, and startup companies that are developing machine learning (ML) and artificial intelligence (AI) applications are going to be prioritized.
Fiona Marshall, senior VP, discovery, preclinical and translational medicine at Merck Research Laboratories, said the biopharmaceutical industry has started to harness opportunity, which was presented by emerging technological developments in machine learning (ML), and artificial intelligence (AI).
She said, the MDSS is going to provide entrepreneurial and collaborative setting where scientists of the company have access to the expertise and tools for fuelling the important innovations that discovery and development of drug.
The digital technologies are enabling new innovation in the drug discovery and development of the company in the areas of target identification, pre-clinical development, clinical development and lead discovery. Through the MDSS, the partners are selectively accelerating and pilot novel and innovative digital technologies, which are strategically aligned with the life science research of Merck.
Currently the programme also includes six startup companies at each network and the interested entrepreneurs can apply on the website of MDSS.